Share >  
Share
Share on Tumblr

Vikas Dandekar

News »

   latest by relevance
PATENTS OR PATIENTS?
May 09, 2012 at 16:10 | Source: Moneycontrol.com
By: Vikas Dandekar, PharmaAsia News
Cipla's price cut is strategic move: Expert
May 04, 2012 at 13:01 | Source: CNBC-TV18
Cipla's move to slash price of its cancer drug by almost 75% is a strong one, this is not only a humanitarian move, but is a strategic play as well, Vikas Dandekar of Pharmasianews.com told CNBC-TV18.
GoM vs pharma industry: Battling for market driven pricing
Apr 03, 2012 at 22:17 | Source: CNBC-TV18
The pharma industry is on the edge of its seat with all eyes on the April 4 Group of Ministers (GoM) meeting which will decide on a final pricing policy for essential drugs, reports CNBC-TV18's Archana Shukla.
Pharma sector moots market-based pricing: Pfizer
Apr 02, 2012 at 16:36 | Source: CNBC-TV18
In an interview to CNBC-TV18, Kewal Handa, managing director of Pfizer and Vikas Dandekar, India Bureau Chief of PharmAsia News.Com discuss the issue of drug pricing.
Biocon-Pfizer insulin deal might collapse soon: PharmAsia
Mar 12, 2012 at 21:59 | Source: CNBC-TV18
The deal between Biocon and Pfizer to market a range of insulin products may be in crisis. Vikas Dandekar, the India Bureau Chief of PharmAsia News who broke this story tells CNBC-TV18 that while sources are saying talks are on to salvage the deal, it is most likely to be called off.
Teva will get part of profit from Lipitor sale by Ranbaxy
Dec 15, 2011 at 09:20 | Source: CNBC-TV18
Industry sources tell PharmAsia News that Ranbaxy forged the Teva Lipitor deal as a back-up plan to try and ensure an on-time launch.

Videos »
Cipla's price cut is strategic move: Expert
GoM vs pharma industry: Battling for market driven pricing
Pharma sector moots market-based pricing: Pfizer
Biocon-Pfizer insulin deal might collapse soon: PharmAsia
Teva will get part of profit from Lipitor sale by Ranbaxy
more »

Photos »

  /  
Related News »
India Faces Shocking Lapse in Drug Safety Norms
Drug expert Vikas Dandekar commented, "Unapproved drugs have been allowed to be marketed in India, questionable combinations have been allowed to be marketed in India, so all of these will have to be probed very closely. And this will definitely blow up ...
May 15, 2012 at 13:09 | Source: Silicon India

Follow moneycontrol.com

Facebook Twitter Google Plus RSS Wap SMS SMS Alert iPad iPhone Blackberry OVI Android Window